,8 CuATSM is currently in Phase II/III clinical trials in Australia (NCT04082832) after repeated reports that CuATSM treatment slows disease progression and improves survival in several mouse models of SOD1-associated ALS.8, 9, 10, 11, 12, 13 CuATSM has been shown to act via several mechanisms, including reducing peroxynitrate levels,8 restoring mitochondrial function,14,15 and having anti-ferroptotic activity.16 The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.